Good luck there Ms Yellen. Celgene to buy very soon, so you might be waiting some time on those lower prices.
Over the years since the GE agreement, Ma has made forward statements(implied and outright) at many quarterly CCs. Here are just a few;
-We are working with getting new agreements with OEM's. This relates to having sales force sell other brand name medical devises. New hire from Seimans implied that might be one company. But, NOTHING
-Getting more devices from GE to sell. But, NOTHING
- Very excited about prospects in India for EECP. But, NOTHING
-Great accretive acquisition in China. Stock was almost 2 times higher when done. A Bold face Lie. Worse than NOTHING
-2 years and 3 million share giveaway to RIOS. We will be getting expanded insurance coverage. But, NOTHING
-Company sponsored stroke trial to start. But, NOTHING
-We will be profitable 2 Q's ago. But, NOTHING
-We are working with CMS on the CED program for EECP. But, NOTHING
-Ma says company undervalued and he will buy some in personal account. Then, reconsiders....So, NOTHING
-Ma says we haven't given up on EECP.....
-Ma says we are a growth company.....
Ma says buyback wasn't to accommodate Dempsey shares.......
Wow, this guy really earns his 600,000 dollar pay package.
All relates to CHF. Heres a release from Cyberonics. Note the very slight improvement in in ejection. This is no better than eecp. But, thanks to Ma, we have NO studies
Cyberonics is the leading proponent of such therapy and the six-month heart failure trial, involving 60 patients, used its system to stimulate both the left and right-sided vagus nerve.
Patients, on average, showed a 4.5 percent improvement in left ventricular ejection fraction, a key measure of heart function, the study found, and there was no difference in the results between the left and right sides.
"I think, at six months, that (4.5 percent improvement) is a very impressive achievement," study leader Inder Anand from the University of Minnesota told reporters at the European Society of Cardiology annual meeting
Boston Scientific studies failed and Novartis's pill is called "ground breaking" for improving death rates form 17% standard care to 13%. And Cyberonics "very impressive.?" Give me a break. The bar is low on all these treatments and yet Ma has given up on EECP; at a time where the market is 'begging" for a cost effective, cost reducing(hospital stays) solution.
Studies by vaso should have started 3 years ago, when vaso got a lifeline from GE. Instead, our Chinese CEO decided to put all our cards on his "motherland" by buying Chinese company. Ma is a failure and strategy is same. China is a money pit for VASO. Ma should be FIRED. Castle awards Ma a 600,000 dollar a year financial package. And, Castle gets paid right back for his "excellent' work on the compensation committee. Whats wrong with this picture???????????????
Vaso has been going to trade shows in Brazil for 3 years now. No sales but now we have approval.?(Who knew we didn't even have approval there?) Maybe sales in a couple more years. And no Mobi.
This is not an acceptable way to spend shareholder money; going to trade shows in countrys where we cant even sell product because there is no current approval. Where is shareholder return for all these travel expenses? How many years before vaso sees a return on all these "travel investments."
Shareholders demand news on EECP (trial, insurance coverage, new indications, CED..) in NORTH AMERICA. That is the only thing that will move the needle here............other than Ma taking a permanent vacation.
Spoor should cut the BS. We are "progressing well through P2". That's just great, considering they were supposed to be done with this trial months ago. A CEO should address these concerns, and not put out a PR statement that ignores the obvious.
How many times have we heard this type of exaggeration after one of these international trade shows? At some point, this type of hyperbole does all shareholders a disservice as it makes all of managements statements less and less credible.
And since vaso never breaks out sales on a country by country basis, no shareholder can ever check the eventual validity of these statements as they relate to future sales.
Vaso needs to cut the BS, and just show shareholders results. These many trade shows over the years have done NOTHING for device sales to date.
They did a block of 12,000 at .95 yesterday. Some were a roll, as partial profit taking on the oct 22 1/2's were sold. Stock heading to that 25 strike + by years end
Sales? Can it be?
They obviously have been reading this board and the disgust that shareholders have with the typical no details but "great interest" comments these trade shows get.
This blog is much more detailed than the original one we all panned. I don't know when, if ever, they have told us about an EECP sale. This is all great, but why does it take a message board for these knuckleheads to figure out what is important to us and the market.
And, as you say, this is the type of PR that deserves a real release.
During the exhibition we closed multiple sales deals, including the sale of the Lumenair™ EECP® Therapy system used for live demonstrations in the show right out of the booth.
If this is true, and we get some real follow through on sales, it is not priced in to the share price. The problem with management here is that they have no credibility. They promoted excitement in India sales recently, and share price rose according, only to completely disappoint.
If they deliver now, shares are a steal and the big buying going on for months at around 25 cents will seem like a real bargain. We shall see.............................
For better or worse, JJ aint going nowhere. He worked for over a year with no real pay, and now has plenty of stock and options. Payday for him(and more importantly us) is just around the corner.
This has been one well planned out "drop and pop."
No deal will ever get done. This reminds me of TRQ.
Mongolia................Venezuela...................same dog, different fleas